Germany's IQWiG Calls For Wider Availability Of Comparative Effectiveness Data
This article was originally published in The Pink Sheet Daily
Executive SummaryA draft law also would raise the profile of Germany's cost-effectiveness watchdog, but perhaps not empower it as much as it hopes.
You may also be interested in...
A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.